drugset / Trial / NCT06140095

Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

NCT06140095

Phase 0 Unknown 8 enrolled Region Stockholm Amgen · collab
NaSingle-groupOpen-labelBasic science

Summary

Eight healthy male volunteers will be studied in consecutive sessions regarding the acute effect of evolocumab and atorvastatin on cholesterol and bile metabolism.

Timeline

Start
2024-02
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg
Subject Evolocumab Monoclonal antibody 140 mg Subcutaneous

Indications

No indication recorded.